Refractory Glaucoma

Patients with uncontrolled refractory glaucoma who underwent MicroPulse transscleral cyclophotocoagulation experienced a mean 28.6% IOP reduction from baseline at 2 years, according to a study.

A low-cost nonvalved aqueous drainage implant significantly reduced IOP and glaucoma medication use in patients with refractory glaucoma, according to a retrospective review.

The Xen45 gel stent showed promising short-term safety and efficacy in patients with refractory glaucoma, according to a poster presented at the virtual Association for Research in Vision and Ophthalmology meeting.

China’s National Medical Products Administration approved the use of the Xen gel stent for the surgical management of patients with refractory glaucoma, according to an Allergan press release.

Glaukos has completed patient enrollment in an FDA investigational device exemption trial for the iStent infinite trabecular micro-bypass system.